Keyword: Regeneron Pharmaceuticals
The Medicines Company announced long-term data for inclisiran, showing that the drug lowered “bad” LDL cholesterol by more than 50%.
Adimab is continuing a dealmaking streak with three more deal expansions, with Novartis, Regeneron and Takeda.
Though biopharmas seem to be using their R&D dollars more effectively, they are only converting 24% of new molecular entities to approved drugs.
The deal gives Regeneron access to technology designed to conserve the functional and structural integrity of targets.
Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Regeneron and Sanofi’s Dupixent.
The move gives Sanofi the right to opt-in to two bispecific programs but otherwise leaves each company free to operate independently.
Sanofi and Regeneron's new immuno-oncology drug is the sixth PD-1 inhibitor to win FDA approval, but it has niche market to itself.
The strong early signs of efficacy led Regeneron to target a 2019 start date for a potentially registrational phase 2 study.
Kronos Bio snagged Regeneron’s business development director, Philip Gutry, to be its chief business officer and manage its pipeline alliances.
Clearside Biomedical has cratered after revealing its top drug failed a phase 3 trial in retinal vein occlusion, a common cause of vision loss.